25 XP   0   0   10

Alpine Immune Sciences Inc
Buy, Hold or Sell?

Let's analyse Alpine Immune Sciences Inc together

PenkeI guess you are interested in Alpine Immune Sciences Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Alpine Immune Sciences Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Alpine Immune Sciences Inc

I send you an email if I find something interesting about Alpine Immune Sciences Inc.

Quick analysis of Alpine Immune Sciences Inc (30 sec.)










What can you expect buying and holding a share of Alpine Immune Sciences Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$5.00
Expected worth in 1 year
$7.27
How sure are you?
18.9%

+ What do you gain per year?

Total Gains per Share
$2.27
Return On Investment
3.5%

For what price can you sell your share?

Current Price per Share
$64.43
Expected price per share
$34.25 - $
How sure are you?
50%

1. Valuation of Alpine Immune Sciences Inc (5 min.)




Live pricePrice per Share (EOD)

$64.43

Intrinsic Value Per Share

$-11.89 - $-14.02

Total Value Per Share

$-6.89 - $-9.01

2. Growth of Alpine Immune Sciences Inc (5 min.)




Is Alpine Immune Sciences Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$327.9m$144m$63m30.4%

How much money is Alpine Immune Sciences Inc making?

Current yearPrevious yearGrowGrow %
Making money-$7.4m-$14.3m$6.8m91.1%
Net Profit Margin-91.9%-307.2%--

How much money comes from the company's main activities?

3. Financial Health of Alpine Immune Sciences Inc (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#167 / 1016

Most Revenue
#259 / 1016

Most Profit
#502 / 1016

Most Efficient
#567 / 1016

What can you expect buying and holding a share of Alpine Immune Sciences Inc? (5 min.)

Welcome investor! Alpine Immune Sciences Inc's management wants to use your money to grow the business. In return you get a share of Alpine Immune Sciences Inc.

What can you expect buying and holding a share of Alpine Immune Sciences Inc?

First you should know what it really means to hold a share of Alpine Immune Sciences Inc. And how you can make/lose money.

Speculation

The Price per Share of Alpine Immune Sciences Inc is $64.43. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Alpine Immune Sciences Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Alpine Immune Sciences Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $5.00. Based on the TTM, the Book Value Change Per Share is $0.57 per quarter. Based on the YOY, the Book Value Change Per Share is $0.22 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Alpine Immune Sciences Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps0.090.1%-0.12-0.2%-0.22-0.3%-0.16-0.2%-0.13-0.2%
Usd Book Value Change Per Share2.543.9%0.570.9%0.220.3%0.220.3%0.140.2%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share2.543.9%0.570.9%0.220.3%0.220.3%0.140.2%
Usd Price Per Share19.06-12.13-8.01-8.88-7.74-
Price to Earnings Ratio52.40-3.51--10.63--9.87--6.70-
Price-to-Total Gains Ratio7.51--1,121.91--80.71--286.62--188.87-
Price to Book Ratio3.81-3.85-3.99-8.49-7.25-
Price-to-Total Gains Ratio7.51--1,121.91--80.71--286.62--188.87-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share64.43
Number of shares15
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.570.22
Usd Total Gains Per Share0.570.22
Gains per Quarter (15 shares)8.503.24
Gains per Year (15 shares)33.9912.97
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1034240133
20685802616
301029203929
4013612605242
5017016006555
6020419407868
7023822809181
80272262010494
903062960117107
1003403300130120

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.03.00.025.0%1.011.00.08.3%1.019.00.05.0%3.034.00.08.1%3.034.00.08.1%
Book Value Change Per Share1.03.00.025.0%3.09.00.025.0%5.015.00.025.0%7.030.00.018.9%7.030.00.018.9%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.037.00.0%0.00.037.00.0%
Total Gains per Share1.03.00.025.0%3.09.00.025.0%5.015.00.025.0%7.030.00.018.9%7.030.00.018.9%

Fundamentals of Alpine Immune Sciences Inc

About Alpine Immune Sciences Inc

Alpine Immune Sciences, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of immunotherapies through protein engineering technologies for treating autoimmune and inflammatory diseases. The company's product pipeline includes Povetacicept, a dual B cell cytokine antagonist, which is in Phase 2 clinical trial for the treatment of multiple autoimmune and inflammatory diseases; and Acazicolcept, a dual inhibitor of the CD28 and ICOS T cell costimulatory pathways that is in preclinical trial for the treatment of systemic lupus erythematosus. It is also developing RUBY-3 that has completed Phase 1 clinical trial for the treatment of glomerulonephritis; and RUBY-4, which has completed Phase 1 clinical trial for the treatment of cytopenias. The company was incorporated in 2007 and is headquartered in Seattle, Washington.

Fundamental data was last updated by Penke on 2024-04-11 00:13:05.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is cheap.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Alpine Immune Sciences Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Alpine Immune Sciences Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Alpine Immune Sciences Inc to the Biotechnology industry mean.
  • A Net Profit Margin of 19.3% means that $0.19 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Alpine Immune Sciences Inc:

  • The MRQ is 19.3%. The company is making a huge profit. +2
  • The TTM is -91.9%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ19.3%TTM-91.9%+111.3%
TTM-91.9%YOY-307.2%+215.2%
TTM-91.9%5Y-585.7%+493.8%
5Y-585.7%10Y-643.5%+57.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ19.3%-197.2%+216.5%
TTM-91.9%-210.4%+118.5%
YOY-307.2%-279.3%-27.9%
5Y-585.7%-436.8%-148.9%
10Y-643.5%-599.3%-44.2%
1.1.2. Return on Assets

Shows how efficient Alpine Immune Sciences Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Alpine Immune Sciences Inc to the Biotechnology industry mean.
  • 1.6% Return on Assets means that Alpine Immune Sciences Inc generated $0.02 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Alpine Immune Sciences Inc:

  • The MRQ is 1.6%. Using its assets, the company is less efficient in making profit.
  • The TTM is -3.2%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ1.6%TTM-3.2%+4.7%
TTM-3.2%YOY-5.6%+2.5%
TTM-3.2%5Y-7.8%+4.6%
5Y-7.8%10Y-9.0%+1.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.6%-13.6%+15.2%
TTM-3.2%-12.9%+9.7%
YOY-5.6%-11.9%+6.3%
5Y-7.8%-14.2%+6.4%
10Y-9.0%-16.2%+7.2%
1.1.3. Return on Equity

Shows how efficient Alpine Immune Sciences Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Alpine Immune Sciences Inc to the Biotechnology industry mean.
  • 1.8% Return on Equity means Alpine Immune Sciences Inc generated $0.02 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Alpine Immune Sciences Inc:

  • The MRQ is 1.8%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is -4.9%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ1.8%TTM-4.9%+6.7%
TTM-4.9%YOY-10.6%+5.6%
TTM-4.9%5Y-16.8%+11.8%
5Y-16.8%10Y-13.5%-3.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.8%-17.0%+18.8%
TTM-4.9%-16.1%+11.2%
YOY-10.6%-15.4%+4.8%
5Y-16.8%-20.0%+3.2%
10Y-13.5%-21.1%+7.6%

1.2. Operating Efficiency of Alpine Immune Sciences Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Alpine Immune Sciences Inc is operating .

  • Measures how much profit Alpine Immune Sciences Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Alpine Immune Sciences Inc to the Biotechnology industry mean.
  • An Operating Margin of 5.0% means the company generated $0.05  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Alpine Immune Sciences Inc:

  • The MRQ is 5.0%. The company is operating less efficient.
  • The TTM is -107.6%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ5.0%TTM-107.6%+112.7%
TTM-107.6%YOY-316.3%+208.7%
TTM-107.6%5Y-588.0%+480.3%
5Y-588.0%10Y-747.5%+159.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ5.0%-286.1%+291.1%
TTM-107.6%-224.4%+116.8%
YOY-316.3%-288.4%-27.9%
5Y-588.0%-475.2%-112.8%
10Y-747.5%-624.7%-122.8%
1.2.2. Operating Ratio

Measures how efficient Alpine Immune Sciences Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.95 means that the operating costs are $0.95 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Alpine Immune Sciences Inc:

  • The MRQ is 0.950. The company is less efficient in keeping operating costs low.
  • The TTM is 2.232. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ0.950TTM2.232-1.282
TTM2.232YOY4.188-1.956
TTM2.2325Y9.563-7.331
5Y9.56310Y13.894-4.331
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.9502.997-2.047
TTM2.2323.247-1.015
YOY4.1883.766+0.422
5Y9.5635.675+3.888
10Y13.8947.857+6.037

1.3. Liquidity of Alpine Immune Sciences Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Alpine Immune Sciences Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 7.86 means the company has $7.86 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Alpine Immune Sciences Inc:

  • The MRQ is 7.862. The company is very able to pay all its short-term debts. +2
  • The TTM is 4.759. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ7.862TTM4.759+3.103
TTM4.759YOY3.297+1.461
TTM4.7595Y4.018+0.741
5Y4.01810Y10.139-6.121
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ7.8623.930+3.932
TTM4.7594.251+0.508
YOY3.2975.436-2.139
5Y4.0186.045-2.027
10Y10.1396.363+3.776
1.3.2. Quick Ratio

Measures if Alpine Immune Sciences Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Alpine Immune Sciences Inc to the Biotechnology industry mean.
  • A Quick Ratio of 14.57 means the company can pay off $14.57 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Alpine Immune Sciences Inc:

  • The MRQ is 14.570. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 8.820. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ14.570TTM8.820+5.750
TTM8.820YOY5.736+3.085
TTM8.8205Y6.304+2.516
5Y6.30410Y16.654-10.349
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ14.5703.629+10.941
TTM8.8204.065+4.755
YOY5.7365.397+0.339
5Y6.3045.993+0.311
10Y16.6546.277+10.377

1.4. Solvency of Alpine Immune Sciences Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Alpine Immune Sciences Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Alpine Immune Sciences Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.14 means that Alpine Immune Sciences Inc assets are financed with 14.1% credit (debt) and the remaining percentage (100% - 14.1%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Alpine Immune Sciences Inc:

  • The MRQ is 0.141. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.288. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.141TTM0.288-0.147
TTM0.288YOY0.449-0.161
TTM0.2885Y0.458-0.170
5Y0.45810Y0.372+0.086
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1410.332-0.191
TTM0.2880.334-0.046
YOY0.4490.268+0.181
5Y0.4580.366+0.092
10Y0.3720.390-0.018
1.4.2. Debt to Equity Ratio

Measures if Alpine Immune Sciences Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Alpine Immune Sciences Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 16.4% means that company has $0.16 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Alpine Immune Sciences Inc:

  • The MRQ is 0.164. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.423. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.164TTM0.423-0.259
TTM0.423YOY0.849-0.426
TTM0.4235Y1.127-0.705
5Y1.12710Y0.648+0.479
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1640.381-0.217
TTM0.4230.390+0.033
YOY0.8490.334+0.515
5Y1.1270.434+0.693
10Y0.6480.466+0.182

2. Market Valuation of Alpine Immune Sciences Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Alpine Immune Sciences Inc generates.

  • Above 15 is considered overpriced but always compare Alpine Immune Sciences Inc to the Biotechnology industry mean.
  • A PE ratio of 52.40 means the investor is paying $52.40 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Alpine Immune Sciences Inc:

  • The EOD is 177.145. Based on the earnings, the company is expensive. -2
  • The MRQ is 52.404. Based on the earnings, the company is expensive. -2
  • The TTM is 3.514. Based on the earnings, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD177.145MRQ52.404+124.741
MRQ52.404TTM3.514+48.890
TTM3.514YOY-10.627+14.141
TTM3.5145Y-9.872+13.387
5Y-9.87210Y-6.695-3.177
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD177.145-2.315+179.460
MRQ52.404-2.560+54.964
TTM3.514-2.664+6.178
YOY-10.627-4.122-6.505
5Y-9.872-6.258-3.614
10Y-6.695-6.108-0.587
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Alpine Immune Sciences Inc:

  • The EOD is -55.320. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -16.365. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -10.558. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-55.320MRQ-16.365-38.955
MRQ-16.365TTM-10.558-5.807
TTM-10.558YOY1.056-11.613
TTM-10.5585Y-7.631-2.927
5Y-7.63110Y-6.409-1.222
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-55.320-3.067-52.253
MRQ-16.365-3.251-13.114
TTM-10.558-3.545-7.013
YOY1.056-5.595+6.651
5Y-7.631-8.315+0.684
10Y-6.409-8.708+2.299
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Alpine Immune Sciences Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 3.81 means the investor is paying $3.81 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Alpine Immune Sciences Inc:

  • The EOD is 12.878. Based on the equity, the company is expensive. -2
  • The MRQ is 3.810. Based on the equity, the company is fair priced.
  • The TTM is 3.854. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD12.878MRQ3.810+9.068
MRQ3.810TTM3.854-0.044
TTM3.854YOY3.994-0.140
TTM3.8545Y8.487-4.633
5Y8.48710Y7.250+1.237
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD12.8781.905+10.973
MRQ3.8102.111+1.699
TTM3.8542.095+1.759
YOY3.9942.836+1.158
5Y8.4873.443+5.044
10Y7.2503.794+3.456
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Alpine Immune Sciences Inc.

3.1. Institutions holding Alpine Immune Sciences Inc

Institutions are holding 91.198% of the shares of Alpine Immune Sciences Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Decheng Capital LLC10.808237.7199708328870832880
2023-12-31RA Capital Management, LLC7.49171.461649097632185854.6595
2023-12-31Great Point Partners LLC5.65112.0307370343362480020.2947
2023-12-31Paradigm Biocapital Advisors LP4.84732.8348317674375500031.1759
2023-12-31BlackRock Inc4.66690.0015305849870658130.0428
2023-12-31Cormorant Asset Management, LLC3.8912.3212255000065000034.2105
2023-12-31Orbimed Advisors, LLC3.86850.9652535245-1546347-37.8859
2023-12-31Vanguard Group Inc3.410.0009223476775988851.5221
2023-12-31T. Rowe Price Associates, Inc.2.57460.0043168727829083420.8268
2023-12-31COMMODORE CAPITAL LP2.45672.6813161000028500021.5094
2023-12-31State Street Corporation2.1210.00131390029784484129.5501
2023-12-31Franklin Resources Inc1.86210.0109122033312203330
2023-12-31Woodline Partners LP1.5260.20731000106-38671-3.7227
2023-12-31Vivo Capital, LLC1.25011.2786819275-95638-10.4532
2023-12-31Geode Capital Management, LLC1.16630.001576434713542221.5323
2023-09-30Octagon Capital Advisors LP1.14441.319375000000
2023-12-31Morgan Stanley - Brokerage Accounts1.09670.00127187416652681244.1195
2023-12-31Adage Capital Partners Gp LLC1.09040.02827145907145900
2023-12-31HHG PLC0.890.00665832395832390
2023-12-31Ikarian Capital, LLC0.74350.86964872484872480
Total 62.556463.745740996923+14283904+34.8%

3.2. Funds holding Alpine Immune Sciences Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-03-28SPDR® S&P Biotech ETF2.98221.02621954736246401.2766
2024-02-29Vanguard Total Stock Mkt Idx Inv1.93960.0029127132900
2023-12-31US Small-Cap Growth II Equity Comp1.6870.0849110573723771527.3858
2023-12-31T. Rowe Price New Horizons1.6870.0852110573723771527.3858
2024-03-28iShares Russell 2000 ETF1.43590.0579411964530.0482
2024-02-29Franklin Biotechnology Discv A(acc)USD1.08811.361713200-111400-13.5096
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr0.88650.020158103577991.3605
2024-02-29Candriam Eqs L Biotech C USD Cap0.74761.0549000000
2024-02-29Franklin Biotechnology Discovery A0.5911.418538737400
2024-03-28iShares Biotechnology ETF0.51290.174633617800
2024-01-31Fidelity Small Cap Index0.50270.035432953347481.4619
2024-01-31TIAA-CREF Quant Small-Cap Equity Instl0.38040.22152493302493300
2024-03-31Direxion Daily S&P Biotech Bull 3X ETF0.3580.7447234625-1646-0.6967
2024-02-29Fidelity Extended Market Index0.34060.020522325230021.363
2024-02-29Fidelity Select Biotechnology0.33690.158222080000
2024-03-28Invesco Dorsey Wright SmallCap Momt ETF0.33580.754122009200
2023-12-31T. Rowe Price Health Sciences0.32540.02762133002133000
2024-03-29Schwab US Small-Cap ETF™0.31960.048620950600
2024-02-29State St Russell Sm/Mid Cp® Indx NL Cl C0.30590.016920050380004.1558
2024-03-28iShares Russell 2000 Growth ETF0.27080.0604177475-206-0.1159
Total 17.03397.368311164938+873450+7.8%

3.3. Insider Transactions

Insiders are holding 4.634% of the shares of Alpine Immune Sciences Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-01-25James Paul RickeySELL23622
2023-12-27Mitchell GoldSELL2957320.04
2023-12-27Peter A ThompsonSELL18149819.96
2023-12-22Mitchell GoldSELL3782520.43
2023-12-19Mitchell GoldSELL240220.01
2023-12-18James Paul RickeySELL180019
2023-12-14James Paul RickeySELL1160019
2023-12-12Mitchell GoldSELL4106317.32
2023-12-08Mitchell GoldSELL806717.08
2023-12-05James Paul RickeySELL41816.01
2023-11-30James Paul RickeySELL70016
2023-11-06James Paul RickeySELL1800316.03

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Alpine Immune Sciences Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--2.5370.566+348%0.223+1037%0.216+1074%0.135+1776%
Book Value Per Share--5.0033.160+58%2.198+128%1.589+215%1.268+295%
Current Ratio--7.8624.759+65%3.297+138%4.018+96%10.139-22%
Debt To Asset Ratio--0.1410.288-51%0.449-69%0.458-69%0.372-62%
Debt To Equity Ratio--0.1640.423-61%0.849-81%1.127-85%0.648-75%
Dividend Per Share----0%-0%-0%-0%
Eps--0.091-0.123+235%-0.220+342%-0.160+276%-0.129+242%
Free Cash Flow Per Share---0.291-0.303+4%-0.168-42%-0.111-62%-0.099-66%
Free Cash Flow To Equity Per Share--2.0980.327+542%0.223+840%0.233+800%0.167+1160%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---14.016--------
Intrinsic Value_10Y_min---11.890--------
Intrinsic Value_1Y_max---0.809--------
Intrinsic Value_1Y_min---0.794--------
Intrinsic Value_3Y_max---2.885--------
Intrinsic Value_3Y_min---2.745--------
Intrinsic Value_5Y_max---5.508--------
Intrinsic Value_5Y_min---5.073--------
Market Cap4223135223.000+70%1249308666.000794910327.750+57%524860395.750+138%581754410.550+115%507043371.405+146%
Net Profit Margin--0.193-0.919+576%-3.072+1690%-5.857+3132%-6.435+3431%
Operating Margin--0.050-1.076+2247%-3.163+6409%-5.880+11827%-7.475+15008%
Operating Ratio--0.9502.232-57%4.188-77%9.563-90%13.894-93%
Pb Ratio12.878+70%3.8103.854-1%3.994-5%8.487-55%7.250-47%
Pe Ratio177.145+70%52.4043.514+1391%-10.627+120%-9.872+119%-6.695+113%
Price Per Share64.430+70%19.06012.128+57%8.008+138%8.876+115%7.736+146%
Price To Free Cash Flow Ratio-55.320-238%-16.365-10.558-35%1.056-1650%-7.631-53%-6.409-61%
Price To Total Gains Ratio25.393+70%7.512-1121.915+15035%-80.707+1174%-286.617+3915%-188.873+2614%
Quick Ratio--14.5708.820+65%5.736+154%6.304+131%16.654-13%
Return On Assets--0.016-0.032+304%-0.056+461%-0.078+599%-0.090+675%
Return On Equity--0.018-0.049+371%-0.106+681%-0.168+1022%-0.135+843%
Total Gains Per Share--2.5370.566+348%0.223+1037%0.216+1074%0.135+1776%
Usd Book Value--327941000.000207125750.000+58%144098000.000+128%104138500.000+215%83104388.541+295%
Usd Book Value Change Per Share--2.5370.566+348%0.223+1037%0.216+1074%0.135+1776%
Usd Book Value Per Share--5.0033.160+58%2.198+128%1.589+215%1.268+295%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps--0.091-0.123+235%-0.220+342%-0.160+276%-0.129+242%
Usd Free Cash Flow---19085000.000-19874750.000+4%-11041500.000-42%-7295800.000-62%-6497430.378-66%
Usd Free Cash Flow Per Share---0.291-0.303+4%-0.168-42%-0.111-62%-0.099-66%
Usd Free Cash Flow To Equity Per Share--2.0980.327+542%0.223+840%0.233+800%0.167+1160%
Usd Market Cap4223135223.000+70%1249308666.000794910327.750+57%524860395.750+138%581754410.550+115%507043371.405+146%
Usd Price Per Share64.430+70%19.06012.128+57%8.008+138%8.876+115%7.736+146%
Usd Profit--5960000.000-7482000.000+226%-14300750.000+340%-10362800.000+274%-8549518.081+243%
Usd Revenue--30853000.00014719000.000+110%7516000.000+310%6172900.000+400%3511864.865+779%
Usd Total Gains Per Share--2.5370.566+348%0.223+1037%0.216+1074%0.135+1776%
 EOD+5 -3MRQTTM+31 -2YOY+28 -55Y+28 -510Y+26 -7

4.2. Fundamental Score

Let's check the fundamental score of Alpine Immune Sciences Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15177.145
Price to Book Ratio (EOD)Between0-112.878
Net Profit Margin (MRQ)Greater than00.193
Operating Margin (MRQ)Greater than00.050
Quick Ratio (MRQ)Greater than114.570
Current Ratio (MRQ)Greater than17.862
Debt to Asset Ratio (MRQ)Less than10.141
Debt to Equity Ratio (MRQ)Less than10.164
Return on Equity (MRQ)Greater than0.150.018
Return on Assets (MRQ)Greater than0.050.016
Total6/10 (60.0%)

4.3. Technical Score

Let's check the technical score of Alpine Immune Sciences Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5083.405
Ma 20Greater thanMa 5046.655
Ma 50Greater thanMa 10039.076
Ma 100Greater thanMa 20029.378
OpenGreater thanClose64.420
Total4/5 (80.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-12-312023-03-312023-06-302023-09-302023-12-31
Accumulated Other Comprehensive Income  -1,121714-407-243-650110-540937397
Income before Tax  -18,3165,050-13,266110-13,1561,434-11,72217,7856,063
Net Income  -18,8647,854-11,010-2,146-13,1561,434-11,72217,6825,960
EBIT  -20,3694,777-15,5922,464-13,1281,406-11,72213,2691,547
EBITDA  -18,2295,033-13,196210-12,9861,410-11,57613,2711,695
Operating Income  -20,3694,777-15,592-63-15,6551,105-14,55016,0971,547
Net Income from Continuing Operations  -18,8645,598-13,266110-13,1561,434-11,72217,6825,960



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets381,812
Total Liabilities53,871
Total Stockholder Equity327,941
 As reported
Total Liabilities 53,871
Total Stockholder Equity+ 327,941
Total Assets = 381,812

Assets

Total Assets381,812
Total Current Assets330,034
Long-term Assets51,778
Total Current Assets
Cash And Cash Equivalents 43,921
Short-term Investments 283,491
Net Receivables 749
Other Current Assets 1,873
Total Current Assets  (as reported)330,034
Total Current Assets  (calculated)330,034
+/-0
Long-term Assets
Property Plant Equipment 8,994
Long Term Investments 40,556
Long-term Assets Other 268
Long-term Assets  (as reported)51,778
Long-term Assets  (calculated)49,818
+/- 1,960

Liabilities & Shareholders' Equity

Total Current Liabilities41,980
Long-term Liabilities11,891
Total Stockholder Equity327,941
Total Current Liabilities
Short-term Debt 912
Accounts payable 3,593
Other Current Liabilities 21,187
Total Current Liabilities  (as reported)41,980
Total Current Liabilities  (calculated)25,692
+/- 16,288
Long-term Liabilities
Capital Lease Obligations 9,914
Long-term Liabilities  (as reported)11,891
Long-term Liabilities  (calculated)9,914
+/- 1,977
Total Stockholder Equity
Common Stock60
Retained Earnings -256,145
Accumulated Other Comprehensive Income 397
Other Stockholders Equity 583,629
Total Stockholder Equity (as reported)327,941
Total Stockholder Equity (calculated)327,941
+/-0
Other
Capital Stock60
Cash and Short Term Investments 327,412
Common Stock Shares Outstanding 60,347
Current Deferred Revenue16,288
Liabilities and Stockholders Equity 381,812
Net Debt -34,007
Net Invested Capital 327,941
Net Working Capital 288,054
Property Plant and Equipment Gross 11,827
Short Long Term Debt Total 9,914



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-31
> Total Assets 
0
0
0
28,543
26,302
101,247
93,842
87,909
80,937
74,565
67,342
61,935
53,009
49,644
90,786
85,222
80,699
73,124
64,508
54,873
67,105
70,087
64,739
54,093
49,849
102,695
154,033
144,090
129,977
159,818
233,480
255,900
233,938
215,826
291,599
286,686
262,100
252,836
240,547
381,812
381,812240,547252,836262,100286,686291,599215,826233,938255,900233,480159,818129,977144,090154,033102,69549,84954,09364,73970,08767,10554,87364,50873,12480,69985,22290,78649,64453,00961,93567,34274,56580,93787,90993,842101,24726,30228,543000
   > Total Current Assets 
0
0
0
28,442
26,164
101,090
93,647
87,686
80,713
74,214
67,030
61,663
52,937
49,626
88,085
82,548
77,987
71,795
63,080
53,545
64,895
57,222
52,454
42,302
38,088
91,236
142,550
107,101
100,482
139,736
183,749
192,013
176,096
172,289
253,239
240,993
198,784
207,321
197,415
330,034
330,034197,415207,321198,784240,993253,239172,289176,096192,013183,749139,736100,482107,101142,55091,23638,08842,30252,45457,22264,89553,54563,08071,79577,98782,54888,08549,62652,93761,66367,03074,21480,71387,68693,647101,09026,16428,442000
       Cash And Cash Equivalents 
0
0
0
27,812
22,865
100,521
57,555
24,991
16,030
15,416
16,168
24,203
12,929
27,548
11,982
8,000
7,446
3,569
11,473
10,711
41,437
15,468
17,395
16,123
24,446
88,220
141,075
34,959
12,629
18,813
76,099
67,907
34,889
24,360
126,625
13,376
14,465
34,076
18,981
43,921
43,92118,98134,07614,46513,376126,62524,36034,88967,90776,09918,81312,62934,959141,07588,22024,44616,12317,39515,46841,43710,71111,4733,5697,4468,00011,98227,54812,92924,20316,16815,41616,03024,99157,555100,52122,86527,812000
       Short-term Investments 
0
0
0
0
0
0
35,096
62,263
64,182
58,318
50,019
36,832
39,745
21,949
75,219
73,240
69,206
66,376
50,509
41,592
22,519
40,097
29,193
24,397
11,237
1,998
0
70,622
84,185
72,247
104,529
94,396
136,980
143,500
122,237
224,265
180,460
169,724
174,472
283,491
283,491174,472169,724180,460224,265122,237143,500136,98094,396104,52972,24784,18570,62201,99811,23724,39729,19340,09722,51941,59250,50966,37669,20673,24075,21921,94939,74536,83250,01958,31864,18262,26335,096000000
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
128
128
0
0
237
237
0
4,851
686
686
63
297
388
317
45,343
554
25,323
453
1,638
677
709
713
688
878
749
7498786887137096771,63845325,32355445,343317388297636866864,851023723700128128000000000000000
       Other Current Assets 
0
0
0
630
3,300
569
996
432
501
480
843
628
263
129
884
1,180
1,335
1,850
1,098
1,005
939
1,657
5,734
1,096
2,273
955
1,178
1,520
3,351
3,333
2,567
4,710
3,774
2,791
3,700
2,960
3,191
3,237
3,084
1,873
1,8733,0843,2373,1912,9603,7002,7913,7744,7102,5673,3333,3511,5201,1789552,2731,0965,7341,6579391,0051,0981,8501,3351,1808841292636288434805014329965693,300630000
   > Long-term Assets 
0
0
0
101
137
157
195
223
224
351
312
272
72
18
2,701
2,674
2,712
1,329
1,428
1,328
2,210
12,865
12,285
11,791
11,761
11,459
11,483
36,989
29,495
20,082
49,731
63,887
57,842
43,537
38,360
45,693
63,316
45,515
43,132
51,778
51,77843,13245,51563,31645,69338,36043,53757,84263,88749,73120,08229,49536,98911,48311,45911,76111,79112,28512,8652,2101,3281,4281,3292,7122,6742,7011872272312351224223195157137101000
       Property Plant Equipment 
0
0
0
91
127
157
195
213
224
351
312
175
72
18
1,116
1,089
1,127
1,197
1,296
1,196
1,824
12,479
12,031
11,537
11,507
11,205
11,229
11,186
10,925
10,645
10,352
10,553
10,419
10,135
9,989
9,803
9,740
9,549
9,230
8,994
8,9949,2309,5499,7409,8039,98910,13510,41910,55310,35210,64510,92511,18611,22911,20511,50711,53712,03112,4791,8241,1961,2961,1971,1271,0891,116187217531235122421319515712791000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
25,549
18,316
9,120
39,064
52,866
46,948
33,041
28,016
35,481
53,170
35,561
33,502
40,556
40,55633,50235,56153,17035,48128,01633,04146,94852,86639,0649,12018,31625,549000000000000000000000000000
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,453
1,453
1,453
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000001,4531,4531,45300000000000000
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,585
1,585
132
132
132
132
386
386
254
254
254
254
254
35,204
254
317
10,667
4,964
475
361
355
409
0
405
0
0
0040504093553614754,96410,66731725435,2042542542542542543863861321321321321,5851,58500000000000000
> Total Liabilities 
0
0
0
44,296
46,217
6,123
4,465
4,419
4,578
5,873
5,238
6,499
3,789
3,578
7,814
6,305
6,818
6,577
9,524
10,282
10,522
24,666
29,908
24,619
24,990
86,467
86,565
81,932
76,683
115,987
110,655
134,997
118,511
116,290
109,590
107,266
92,557
83,448
78,916
53,871
53,87178,91683,44892,557107,266109,590116,290118,511134,997110,655115,98776,68381,93286,56586,46724,99024,61929,90824,66610,52210,2829,5246,5776,8186,3057,8143,5783,7896,4995,2385,8734,5784,4194,4656,12346,21744,296000
   > Total Current Liabilities 
0
0
0
2,415
4,337
6,123
4,465
4,419
4,578
5,873
5,238
6,499
3,789
3,578
2,724
1,895
2,928
3,426
6,867
8,127
8,848
12,556
13,672
8,681
5,105
28,179
35,849
41,167
43,367
60,246
63,933
69,778
68,165
62,618
68,459
57,996
57,089
53,410
51,818
41,980
41,98051,81853,41057,08957,99668,45962,61868,16569,77863,93360,24643,36741,16735,84928,1795,1058,68113,67212,5568,8488,1276,8673,4262,9281,8952,7243,5783,7896,4995,2385,8734,5784,4194,4656,1234,3372,415000
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
113
0
4,948
490
995
1,508
2,018
2,034
2,048
2,734
2,531
0
418
1,742
119
1,537
3,181
4,426
5,282
5,341
5,239
5,299
5,364
5,265
4,136
2,996
829
870
912
9128708292,9964,1365,2655,3645,2995,2395,3415,2824,4263,1811,5371191,74241802,5312,7342,0482,0342,0181,5089954904,948011300000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
113
0
4,948
490
995
1,508
2,018
2,034
2,048
2,064
2,079
0
418
1,742
119
1,318
2,526
3,742
4,567
4,594
4,622
4,652
4,682
4,547
3,380
2,206
0
0
0
0002,2063,3804,5474,6824,6524,6224,5944,5673,7422,5261,3181191,74241802,0792,0642,0482,0342,0181,5089954904,948011300000000000
       Accounts payable 
0
0
0
929
2,638
3,432
1,552
994
1,196
2,110
1,012
1,921
1,278
815
1,076
193
528
750
440
1,716
743
2,399
5,778
1,543
468
548
742
582
466
1,393
1,839
3,349
1,903
1,812
3,240
4,286
1,662
1,645
3,068
3,593
3,5933,0681,6451,6624,2863,2401,8121,9033,3491,8391,3934665827425484681,5435,7782,3997431,7164407505281931,0768151,2781,9211,0122,1101,1969941,5523,4322,638929000
       Other Current Liabilities 
0
0
0
1,486
1,699
2,691
2,913
3,425
3,382
3,763
4,226
4,578
2,511
2,763
753
430
652
641
4,312
4,363
670
5,518
5,825
5,285
2,551
3,824
5,065
5,777
3,953
4,614
8,653
9,417
9,203
12,525
13,744
14,003
12,030
13,684
17,788
21,187
21,18717,78813,68412,03014,00313,74412,5259,2039,4178,6534,6143,9535,7775,0653,8242,5515,2855,8255,5186704,3634,3126416524307532,7632,5114,5784,2263,7633,3823,4252,9132,6911,6991,486000
   > Long-term Liabilities 
0
0
0
41,880
41,880
0
0
0
0
0
0
0
0
0
5,090
4,410
3,890
3,151
2,657
2,155
1,674
12,110
16,236
15,938
19,885
58,288
50,716
40,765
33,316
55,741
46,722
65,219
50,346
53,672
41,131
49,270
35,468
30,038
27,098
11,891
11,89127,09830,03835,46849,27041,13153,67250,34665,21946,72255,74133,31640,76550,71658,28819,88515,93816,23612,1101,6742,1552,6573,1513,8904,4105,09000000000041,88041,880000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,500
4,039
3,570
3,104
2,631
2,155
1,674
1,191
4,886
4,509
8,169
9,873
8,741
7,602
6,458
5,707
4,547
3,380
2,206
1,025
0
0
0
0
0
0
0000001,0252,2063,3804,5475,7076,4587,6028,7419,8738,1694,5094,8861,1911,6742,1552,6313,1043,5704,0394,50000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
103
93
81
66
320
47
26
0
1,674
12,110
16,236
0
0
36,468
29,988
21,348
15,250
38,621
46,722
50,830
37,346
42,083
30,803
39,185
0
20,475
0
0
0020,475039,18530,80342,08337,34650,83046,72238,62115,25021,34829,98836,4680016,23612,1101,67402647320668193103000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
590
371
320
47
26
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000264732037159000000000000000
> Total Stockholder Equity
0
0
0
-15,752
-19,915
95,124
89,377
83,490
76,359
68,692
62,104
55,436
49,220
46,066
82,972
78,917
73,881
66,547
54,984
44,591
56,583
45,421
34,831
29,474
24,859
16,228
67,468
62,158
53,294
43,831
122,825
120,903
115,427
99,536
182,009
179,420
169,543
169,388
161,631
327,941
327,941161,631169,388169,543179,420182,00999,536115,427120,903122,82543,83153,29462,15867,46816,22824,85929,47434,83145,42156,58344,59154,98466,54773,88178,91782,97246,06649,22055,43662,10468,69276,35983,49089,37795,124-19,915-15,752000
   Common Stock
0
0
0
2
2
15
15
15
15
15
16
16
16
16
1
14
14
14
14
14
19
19
19
19
19
19
24
24
24
24
29
30
30
30
44
46
48
49
49
60
60494948464430303029242424241919191919191414141414116161616151515151522000
   Retained Earnings Total Equity00-250,383-237,227-223,961-205,097-191,824-173,726-166,199-151,032-137,538-126,509-115,866-109,524-103,387-93,459-87,926-81,786-70,311-58,455-46,074-34,938-22,799-14,892-9,384-5,066-192,926-189,216-180,300-172,587-165,154-156,675-148,837-142,274-136,18500000
   Accumulated Other Comprehensive Income 
0
0
0
-1,401
0
0
15
3
3
23
5
-17
-14
-4
-12
-59
-105
-55
-25
-13
-12
9
7
10
-118
-55
-41
53
33
45
15
-273
-1,061
-1,369
-1,669
-1,121
-407
-650
-540
397
397-540-650-407-1,121-1,669-1,369-1,061-27315453353-41-55-1181079-12-13-25-55-105-59-12-4-14-17523331500-1,401000
   Capital Surplus 
0
0
0
0
0
231,294
231,621
232,309
233,016
233,808
234,670
235,737
238,434
238,980
88,049
88,346
88,864
89,387
89,933
90,664
115,031
115,704
116,591
117,371
118,417
119,651
177,009
177,947
179,746
181,300
273,813
287,345
290,184
292,699
388,731
404,456
407,129
420,372
0
0
00420,372407,129404,456388,731292,699290,184287,345273,813181,300179,746177,947177,009119,651118,417117,371116,591115,704115,03190,66489,93389,38788,86488,34688,049238,980238,434235,737234,670233,808233,016232,309231,621231,29400000
   Treasury Stock000000000000000000000000-50,467000000000000000
   Other Stockholders Equity 
0
0
0
111,666
110,416
231,294
231,621
232,309
233,016
233,808
234,670
235,737
238,434
238,980
-2,737
3,124
8,165
16,263
25,425
90,664
115,031
115,704
116,591
117,371
118,417
119,651
177,009
177,947
179,746
181,300
273,813
287,345
290,184
292,699
388,731
404,456
407,129
420,372
424,227
583,629
583,629424,227420,372407,129404,456388,731292,699290,184287,345273,813181,300179,746177,947177,009119,651118,417117,371116,591115,704115,03190,66425,42516,2638,1653,124-2,737238,980238,434235,737234,670233,808233,016232,309231,621231,294110,416111,666000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue58,876
Cost of Revenue-576
Gross Profit58,30058,300
 
Operating Income (+$)
Gross Profit58,300
Operating Expense-102,550
Operating Income-44,250-44,250
 
Operating Expense (+$)
Research Development80,328
Selling General Administrative22,222
Selling And Marketing Expenses0
Operating Expense102,550102,550
 
Net Interest Income (+$)
Interest Income10,002
Interest Expense-98
Other Finance Cost-87
Net Interest Income9,817
 
Pretax Income (+$)
Operating Income-44,250
Net Interest Income9,817
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-32,081-56,419
EBIT - interestExpense = -44,348
-32,081
-32,086
Interest Expense98
Earnings Before Interest and Taxes (EBIT)-44,250-31,983
Earnings Before Interest and Taxes (EBITDA)-43,674
 
After tax Income (+$)
Income Before Tax-32,081
Tax Provision-548
Net Income From Continuing Ops-57,008-32,629
Net Income-32,184
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses103,126
Total Other Income/Expenses Net12,169-9,817
 

Technical Analysis of Alpine Immune Sciences Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Alpine Immune Sciences Inc. The general trend of Alpine Immune Sciences Inc is BULLISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Alpine Immune Sciences Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (100.0%) Bearish trend (-100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Alpine Immune Sciences Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: .

The bearish price targets are: 42.88 > 41.16 > 34.25.

Tweet this
Alpine Immune Sciences Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Alpine Immune Sciences Inc. The current mas is .

The long score for the Moving Averages is 14/14.
The longshort score for the Moving Averages is 14/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Alpine Immune Sciences Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Alpine Immune Sciences Inc. The current macd is 7.67632021.

The long score for the Moving Average Convergence/Divergence (MACD) is 4/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 4/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Alpine Immune Sciences Inc price going up in the near term. +2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Alpine Immune Sciences Inc. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Alpine Immune Sciences Inc price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Alpine Immune Sciences Inc Daily Moving Average Convergence/Divergence (MACD) ChartAlpine Immune Sciences Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Alpine Immune Sciences Inc. The current adx is 46.22.

The long score for the Directional Movement Index (DMI) is 4/7.
The longshort score for the Directional Movement Index (DMI) is 4/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Alpine Immune Sciences Inc shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bullish trend. The ADX is trending up, so the bullish trend is strengthening.
Alpine Immune Sciences Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Alpine Immune Sciences Inc. The current sar is 42.04.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Alpine Immune Sciences Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Alpine Immune Sciences Inc. The current rsi is 83.41. The current phase is Overbought in bull market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Overbought in bull market: Short-term excessive buying, potential for pullback. Consider taking profits, be cautious of potential correction. -1
  • Trending down: The RSI is trending down. -1
Alpine Immune Sciences Inc Daily Relative Strength Index (RSI) ChartAlpine Immune Sciences Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Alpine Immune Sciences Inc. The current phase is Overbought in bull market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 0/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH > 80: The STOCH %K is above 80 and overbought. +2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Alpine Immune Sciences Inc price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Alpine Immune Sciences Inc Daily Stochastic Oscillator ChartAlpine Immune Sciences Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Alpine Immune Sciences Inc. The current cci is 111.21.

The long score for the Commodity Channel Index (CCI) is 1/1.
The longshort score for the Commodity Channel Index (CCI) is 1/(-1 +1).

  • CCI > 100: The CCI is above 100, it indicates that the price is significantly above its average, suggesting a potential overbought condition. +1
Alpine Immune Sciences Inc Daily Commodity Channel Index (CCI) ChartAlpine Immune Sciences Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Alpine Immune Sciences Inc. The current cmo is 74.62.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Alpine Immune Sciences Inc Daily Chande Momentum Oscillator (CMO) ChartAlpine Immune Sciences Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Alpine Immune Sciences Inc. The current willr is -0.46174142.

The long score for the Williams %R is 1/1.
The longshort score for the Williams %R is 1/(-1 +1).

  • WILLR > -20: The Williams %R is above -20. This indicates that the price is in overbought territory, suggesting a potential price correction or trend reversal to the downside. +1
Alpine Immune Sciences Inc Daily Williams %R ChartAlpine Immune Sciences Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Alpine Immune Sciences Inc.

Alpine Immune Sciences Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Alpine Immune Sciences Inc. The current atr is 2.92874557.

Alpine Immune Sciences Inc Daily Average True Range (ATR) ChartAlpine Immune Sciences Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Alpine Immune Sciences Inc. The current obv is 89,863,364.

Alpine Immune Sciences Inc Daily On-Balance Volume (OBV) ChartAlpine Immune Sciences Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Alpine Immune Sciences Inc. The current mfi is 88.29.

The long score for the Money Flow Index (MFI) is 2/2.
The longshort score for the Money Flow Index (MFI) is 2/(-2 +2).

  • MFI > 50: +1
  • MFI > 80: +1
Alpine Immune Sciences Inc Daily Money Flow Index (MFI) ChartAlpine Immune Sciences Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Alpine Immune Sciences Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-27CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-11-28SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2023-11-29STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-01STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-05RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-06STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-08STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-12STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-13BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-15STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-20STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-21STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-22STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-26STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-27STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-28MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-01-03CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-05WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-08STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-09SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-01-10CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-01-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-12STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-17STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-23STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-24DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-25DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-26MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-29MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-30STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-02-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-06RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-02-07STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-09CCI LONG ENTRY SHORT CLOSE100 crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-13RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-15STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-02-16CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-20RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-22STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-27STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-28MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-07STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-08MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-03-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-13STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-18WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-19SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-21MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-22RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-25MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-03-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-03SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-04-04DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-05CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-08DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-10MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-11ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-04-15STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-17STOCH LONG EXITThe %K line crosses below the %D line.

6.3. Candlestick Patterns

Alpine Immune Sciences Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Alpine Immune Sciences Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5083.405
Ma 20Greater thanMa 5046.655
Ma 50Greater thanMa 10039.076
Ma 100Greater thanMa 20029.378
OpenGreater thanClose64.420
Total4/5 (80.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Alpine Immune Sciences Inc with someone you think should read this too:
  • Are you bullish or bearish on Alpine Immune Sciences Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Alpine Immune Sciences Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Alpine Immune Sciences Inc

I send you an email if I find something interesting about Alpine Immune Sciences Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Alpine Immune Sciences Inc.

Receive notifications about Alpine Immune Sciences Inc in your mailbox!